Back to top
Search by company, common medicine name, or title of Risk Minimisation Material
This booklet is intended for patients who have been prescribed XALKORI (crizotinib). The patient alert card shown in the booklet is to help patients understand the risks associated with Xalkori, and remind them to seek immediate medical attention if they experience any listed signs and symptoms
Patient alert card for Xarelto 2.5mg, 10mg, 15mg & 20mg - noting patient's anticoagulation treatment
For Healthcare Professionals
Xarelto Prescriber Guide for Healthcare Professionals
For Healthcare Professionals
Prescriber brochure to provide guidance on assessments prior to prescribing, management, monitoring and safety considerations related to the Risk Management Plan.
For Healthcare Professionals
Prescriber Initiation checklist to remind HCPs of the risks associated with the use of tofacitinib and the recommended tests before and during tofacitinib administration and treatment
For Healthcare Professionals
Prescriber Maintenance checklist to remind HCPs of the risks associated with the use of tofacitinib and the recommended tests before and during tofacitinib administration and treatment
Patient alert card to help patients understand the risks associated with XELJANZ, and remind them to seek immediate medical attention if they experience any listed signs and symptoms.
For Healthcare Professionals
Prescribing checklist before prescribing Xenidate XL 18mg and checklist for ongoing monitoring
For Healthcare Professionals
Prescribing checklist before prescribing Xenidate XL 27mg and checklist for ongoing monitoring
For Healthcare Professionals
Prescribing checklist before prescribing Xenidate XL 36mg prolonged-released tablets and checklist for ongoing monitoring
For Healthcare Professionals
Prescribing checklist before prescribing Xenidate XL 54mg and checklist for ongoing monitoring
For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
For Healthcare Professionals
For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]
This reminder card contains important safety information that patients need to be aware of before and during treatment with denosumab (XGEVA) injections for cancer-related conditions, A side effect called osteonecrosis of the jaw (ONJ, bone damage in the jaw) has been reported commonly (may affect up to 1 in 10 people) in patients receiving XGEVA injections for cancer-related conditions. ONJ can also occur after stopping treatment. It is important to try to prevent ONJ developing as it may be a painful condition that can be difficult to treat. In order to reduce the risk of developing ONJ, there are some precautions patients should take. To request a copy of the patient card, please contact Amgen Medical Information on +44 (0) 1223 436441
This audio guide was created to help you better understand Ximluci when used for the treatment of neovascular (wet) age-related macular degeneration (AMD) including an overview of how Ximluci works, how treatment is administered and important safety information such as the potential side effects and what to do if you experience these during treatment.
This audio guide was created to help you better understand Ximluci when used for the treatment of visual impairment due to choroidal neovascularisation (CNV) including an overview of how Ximluci works, how treatment is administered and important safety information such as the potential side effects and what to do if you experience these during treatment.
This audio guide was created to help you better understand Ximluci when used for the treatment of proliferative diabetic retinopathy and/or visual impairment due to diabetic macular oedema (DMO) including an overview of how Ximluci works, how treatment is administered and important safety information such as the potential side effects and what to do if you experience these during treatment.
This audio guide was created to help you better understand Ximluci when used for the treatment of visual impairment due to retinal vein occlusion (RVO) including an overview of how Ximluci works, how treatment is administered and important safety information such as the potential side effects and what to do if you experience these during treatment.
This booklet was created to help you better understand Ximluci when used for the treatment of neovascular (wet) age-related macular degeneration (AMD) including an overview of how Ximluci works, how treatment is administered and important safety information such as the potential side effects and what to do if you experience these during treatment. An audio version of this booklet is also available on eMC.
This booklet was created to help you better understand Ximluci when used for the treatment of visual impairment due to choroidal neovascularisation (CNV) including an overview of how Ximluci works, how treatment is administered and important safety information such as the potential side effects and what to do if you experience these during treatment. An audio version of this booklet is also available on eMC.
This booklet was created to help you better understand Ximluci when used for the treatment of proliferative diabetic retinopathy and/or visual impairment due to diabetic macular oedema (DMO) including an overview of how Ximluci works, how treatment is administered and important safety information such as the potential side effects and what to do if you experience these during treatment. An audio version of this booklet is also available on eMC.
This booklet was created to help you better understand Ximluci when used for the treatment of visual impairment due to retinal vein occlusion (RVO) including an overview of how Ximluci works, how treatment is administered and important safety information such as the potential side effects and what to do if you experience these during treatment. An audio version of this booklet is also available on eMC.
For Healthcare Professionals
This HCP Educational Information Brochure aims to provide information about Differentiation Syndrome related to XOSPATA (gilteritinib), to minimise the risk associated with this safety concern. The brochure contains the following: -Information on Xospata, including the approved indication according to the SmPC. -Description of the signs and symptoms of differentiation syndrome. -Management of differentiation syndrome
Every Xospata 40 mg film-coated tablets pack contains a patient alert card. The purpose of the patient alert card is to provide: -Information for patients that Xospata treatment may cause differentiation syndrome. -Description of signs or symptoms of the safety concern and when to seek medical care if differentiation syndrome is suspected -A warning message for healthcare professionals treating the patient at any time, including in conditions of emergency, that the patient is using Xospata. -Contact details of the treating physician who has prescribed Xospata. -Needs to be carried all the time and presented to any healthcare professional.
Patient / Parent Guide: Important safety information about serious side effects that you need to be aware of before, during and after treatment.
For Healthcare Professionals
Xromi® (Hydroxycarbamide) Physician Guide: Important information on minimising the risk of medication errors and serious adverse events
For Healthcare Professionals
Guide for Healthcare Professionals:correct use of Xultophy to minimise the risk of medication errors
For Healthcare Professionals
Xylocaine 10mg Spray is supplied with a single use nozzle for the administration of Xylocaine Spray. A multi-pack of 50 individual nozzles are also available separately. If the nozzles are shared among patients, or reused by individual patients, there is a potential risk of cross contamination. Due to this risk, the Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL) and Labelling have been updated with important information on the use of the nozzle.
For Healthcare Professionals
Important information about safe use and handling of Xyrem
For Healthcare Professionals
Important risk minimisation information for patients on how to take Xyrem.
For Healthcare Professionals
Important risk minimisation information for healthcare professionals: Treatment initiation and follow-up visit form
Important risk minimisation information for patients: frequently asked questions (FAQ) Information sheet
Are you a healthcare professional?
Are you a healthcare professional?
Skip to main content